What's on this Page
What is Samarium 153 Lexidronam
Samarium-153 lexidronam is a parenteral radioisotope indicated for the relief of pain associated with metastatic bone cancer.
The onset of analgesic effect is usually within 7 days, with maximum pain relief generally occurring 3 to 4 weeks after administration.
It consists of a stable complex of radioactive samarium and a tetraphosphonate chelator, ethylenediaminetetramethylenephosphonic acid (EDTMP).
Brand Name
QUADRAMET
Indications
- bone pain
Side Effects
- abdominal pain
- alopecia
- anemia
- angina
- arrhythmia exacerbation
- bone fractures
- bone pain
- bradycardia
- candidiasis
- chest pain (unspecified)
- chills
- coagulopathy
- cough
- diarrhea
- disseminated intravascular coagulation (DIC)
- dizziness
- ecchymosis
- epistaxis
- fever
- flushing
- GI bleeding
- heart failure
- hematuria
- hypertension
- hypotension
- infection
- leukopenia
- lymphadenopathy
- myasthenia
- nausea
- ocular hemorrhage
- paresthesias
- purpura
- rash
- stroke
- thrombocytopenia
- vomiting
Monitoring Parameters
- CBC
- pregnancy testing
Contraindications
- accidental exposure
- anorexia nervosa
- bone marrow suppression
- breast-feeding
- cardiac arrhythmias
- chemotherapy
- contraception requirements
- disseminated intravascular coagulation (DIC)
- heart failure
- hypocalcemia
- obesity
- phosphonate hypersensitivity
- pregnancy
- pregnancy testing
- radiation therapy
- renal impairment
- reproductive risk
- urinary incontinence
Interactions
There are no drug interactions associated with Samarium-153 Lexidronam products.
